<?xml version="1.0" encoding="UTF-8"?>
<rss version="2.0"
	xmlns:content="http://purl.org/rss/1.0/modules/content/"
	xmlns:wfw="http://wellformedweb.org/CommentAPI/"
	xmlns:dc="http://purl.org/dc/elements/1.1/"
	xmlns:atom="http://www.w3.org/2005/Atom"
	xmlns:sy="http://purl.org/rss/1.0/modules/syndication/"
	xmlns:slash="http://purl.org/rss/1.0/modules/slash/"
	>

<channel>
	<title>Symptom Advice .com &#187; brain functions</title>
	<atom:link href="http://symptomadvice.com/tag/brain-functions/feed/" rel="self" type="application/rss+xml" />
	<link>http://symptomadvice.com</link>
	<description></description>
	<lastBuildDate>Tue, 29 May 2012 22:17:13 +0000</lastBuildDate>
	<language>en</language>
	<sy:updatePeriod>hourly</sy:updatePeriod>
	<sy:updateFrequency>1</sy:updateFrequency>
	<generator>http://wordpress.org/?v=3.0.1</generator>
		<item>
		<title>Shire&#8217;s Vyvanse demonstrates efficacy in new trial</title>
		<link>http://symptomadvice.com/shires-vyvanse-demonstrates-efficacy-in-new-trial/</link>
		<comments>http://symptomadvice.com/shires-vyvanse-demonstrates-efficacy-in-new-trial/#comments</comments>
		<pubDate>Sun, 22 Aug 2010 22:03:13 +0000</pubDate>
		<dc:creator>Symptom Advice</dc:creator>
				<category><![CDATA[adhd symptoms]]></category>
		<category><![CDATA[brain functions]]></category>
		<category><![CDATA[deficit hyperactivity disorder]]></category>
		<category><![CDATA[hyperactivity]]></category>
		<category><![CDATA[pharmaceutical company]]></category>
		<category><![CDATA[phase iii]]></category>

		<guid isPermaLink="false">http://symptomadvice.com/shires-vyvanse-demonstrates-efficacy-in-new-trial/</guid>
		<description><![CDATA[Posted &#111;&#110; 09/08/2010 &#105;&#110; Pharmaceutical Company Product News Shire &#104;&#097;&#115; published data &#102;&#114;&#111;&#109; &#097; phase IIIb study &#111;&#102; &#105;&#116;&#115; attention deficit hyperactivity disorder (ADHD) drug Vyvanse, demonstrating &#105;&#116;&#115; efficacy &#097;&#109;&#111;&#110;&#103; adult patients.Results published &#105;&#110; &#116;&#104;&#101; medical journal Behavioral and Brain Functions &#115;&#104;&#111;&#119;&#101;&#100; that patients using &#116;&#104;&#101; once-daily Vyvanse Capsule CII treatment benefited &#102;&#114;&#111;&#109; improved attention [...]]]></description>
			<content:encoded><![CDATA[<p></p><p><img src="http://symptomadvice.com/wp-content/uploads/2010/08/1282514593-75.jpg" style="clear:both;clear:both;margin:0 15px 15px 0" />
<p><strong>Posted &#111;&#110; 09/08/2010 &#105;&#110; Pharmaceutical Company Product News </strong></p>
<p>Shire &#104;&#097;&#115; published data &#102;&#114;&#111;&#109; &#097; phase IIIb study &#111;&#102; &#105;&#116;&#115; attention deficit hyperactivity disorder (ADHD) drug Vyvanse, demonstrating &#105;&#116;&#115; efficacy &#097;&#109;&#111;&#110;&#103; adult patients.Results published &#105;&#110; &#116;&#104;&#101; medical journal Behavioral and Brain Functions &#115;&#104;&#111;&#119;&#101;&#100; that patients using &#116;&#104;&#101; once-daily Vyvanse Capsule CII treatment benefited &#102;&#114;&#111;&#109; improved attention spans &#098;&#101;&#116;&#119;&#101;&#101;&#110; &#116;&#119;&#111; and 14 hours after administering.&#105;&#116; &#104;&#097;&#115; previously &#098;&#101;&#101;&#110; proven &#116;&#111; offer similar benefits &#097;&#109;&#111;&#110;&#103; children aged &#098;&#101;&#116;&#119;&#101;&#101;&#110; &#115;&#105;&#120; and 12 &#105;&#110; previous clinical studies.Dr Matthew Brams, study author and clinical assistant professor &#111;&#102; psychiatry at Baylor College &#111;&#102; Medicine, &#115;&#097;&#105;&#100; &#116;&#104;&#105;&#115; illustrates &#116;&#104;&#101; drug&#8217;s benefits for ADHD sufferers wishing &#116;&#111; manage their symptoms &#100;&#117;&#114;&#105;&#110;&#103; &#097; working day.He added: &#8220;Because ADHD symptoms may extend &#105;&#110;&#116;&#111; &#116;&#104;&#101; evening for &#109;&#097;&#110;&#121; adults, &#116;&#104;&#101; availability &#111;&#102; treatments that provide symptom improvement throughout &#116;&#104;&#101; day &#105;&#115; important.&#8221;Earlier &#116;&#104;&#105;&#115; month, &#116;&#104;&#101; company published phase III trial data for &#116;&#104;&#101; hereditary angioedema Firazyr, illustrating &#105;&#116;&#115; efficacy when compared &#116;&#111; placebo.
<p><strong>Other news &#115;&#116;&#111;&#114;&#105;&#101;&#115; &#102;&#114;&#111;&#109; 09/08/2010</strong></p>
<p><strong>Read more &#105;&#110; &#116;&#104;&#101; Zenopa News Archive</strong></p>
<p><strong>How &#116;&#104;&#105;&#115; news &#105;&#115; generated</strong></p></p>
]]></content:encoded>
			<wfw:commentRss>http://symptomadvice.com/shires-vyvanse-demonstrates-efficacy-in-new-trial/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
	</channel>
</rss>
